PharmaCyte reports positive interim results in malignant ascites mouse model study

PharmaCyte Biotech, Inc.

Study conducted by Heidelberg Pharma using colon carcinoma cells from Austrianova Master Cell Bank in mice.
Initial data indicates overall tumor volume (Sugarbaker-index) more accurate than fluorescence for tumor burden.
Objectives include optimizing tumor cell dose, timing curve, and assessment method.
CEO Kenneth Waggoner says study proceeding as hoped; confident all objectives will be achieved.
Malignant ascites has no approved treatment; therapy aims to slow or eliminate fluid accumulation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.